BRPI0719955A2 - Processo para síntese de derivados de fenóxi diaminopirimidina - Google Patents

Processo para síntese de derivados de fenóxi diaminopirimidina

Info

Publication number
BRPI0719955A2
BRPI0719955A2 BRPI0719955-4A2A BRPI0719955A BRPI0719955A2 BR PI0719955 A2 BRPI0719955 A2 BR PI0719955A2 BR PI0719955 A BRPI0719955 A BR PI0719955A BR PI0719955 A2 BRPI0719955 A2 BR PI0719955A2
Authority
BR
Brazil
Prior art keywords
phenomy
diaminopyrimidine
synthesis
derivatives
phenomy derivatives
Prior art date
Application number
BRPI0719955-4A2A
Other languages
English (en)
Inventor
Charles Alois Dvorak
Keena Lynn Green
Gary R Lee
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0719955A2 publication Critical patent/BRPI0719955A2/pt
Publication of BRPI0719955B1 publication Critical patent/BRPI0719955B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
BRPI0719955-4A 2006-10-04 2007-09-24 Processo para síntese de derivados de fenóxi diaminopirimidina BRPI0719955B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84920306P 2006-10-04 2006-10-04
US60/849,203 2006-10-04
PCT/EP2007/060095 WO2008040652A1 (en) 2006-10-04 2007-09-24 Process for synthesis of phenoxy diaminopyrimidine derivatives

Publications (2)

Publication Number Publication Date
BRPI0719955A2 true BRPI0719955A2 (pt) 2014-04-29
BRPI0719955B1 BRPI0719955B1 (pt) 2024-01-09

Family

ID=39004835

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719955-4A BRPI0719955B1 (pt) 2006-10-04 2007-09-24 Processo para síntese de derivados de fenóxi diaminopirimidina

Country Status (15)

Country Link
US (3) US8003788B2 (pt)
EP (2) EP2343281B1 (pt)
JP (2) JP5128603B2 (pt)
KR (1) KR101176701B1 (pt)
CN (2) CN101522641B (pt)
AU (1) AU2007304280B2 (pt)
BR (1) BRPI0719955B1 (pt)
CA (1) CA2664305C (pt)
DK (1) DK2343281T3 (pt)
ES (2) ES2466667T3 (pt)
IL (3) IL197639A (pt)
MX (1) MX2009003257A (pt)
PL (1) PL2343281T3 (pt)
SI (1) SI2343281T1 (pt)
WO (1) WO2008040652A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2343281T3 (en) * 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
PE20160431A1 (es) 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CN105085847B (zh) * 2014-05-23 2018-05-04 中国科学院宁波材料技术与工程研究所 一种磺酰胺化芳香族聚合物、其制备方法及应用
US10195198B2 (en) 2014-07-03 2019-02-05 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
CA2998742C (en) 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
AU2017237929B2 (en) 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
MX381790B (es) * 2016-12-20 2025-03-13 Afferent Pharmaceuticals Inc Sales cristalinas y polimorfos de un antagonista de p2x3.
WO2019209607A1 (en) 2018-04-23 2019-10-31 Merck Sharp & Dohme Corp. Novel process for synthesis of a phenoxy diaminopyrimidine compound
EP3960179B1 (en) 2019-04-30 2026-03-18 Beijing Tide Pharmaceutical Co., Ltd. Method for treating cough by using diaminopyrimidine compound
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
WO2022060945A1 (en) 2020-09-17 2022-03-24 Teva Pharmaceuticals International Gmbh Solid state forms of gefapixant and process for preparation thereof
CN113336680B (zh) * 2021-06-04 2023-10-03 寿光永康化学工业有限公司 一种磺胺的绿色工艺合成方法
CN113801097B (zh) * 2021-09-27 2022-11-22 成都施贝康生物医药科技有限公司 二氢嘧啶类化合物、其制备方法及用途
CN113773300B (zh) * 2021-09-27 2022-10-11 成都施贝康生物医药科技有限公司 磺酰胺类化合物、其制备方法及用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ296532A (en) * 1994-11-24 2000-02-28 F Substituted 5-benzyl-2,4,-diaminopyrimidines
AUPQ968700A0 (en) * 2000-08-28 2000-09-21 Intreat Pty Limited Treatment of urinary incontinence
EP1541575B1 (en) * 2002-07-29 2010-03-03 Sumitomo Chemical Company, Limited Novel process for producing imidazo(1,2-b)pyridazine derivative
PT1725540E (pt) * 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
SE0401716D0 (sv) * 2004-07-02 2004-07-02 Astrazeneca Ab New compounds
DE602005020313D1 (de) * 2004-08-12 2010-05-12 Amgen Inc Bisaryl-sulfonamide
JP4246207B2 (ja) * 2005-02-21 2009-04-02 住友化学株式会社 除草剤組成物
ATE529413T1 (de) * 2005-09-01 2011-11-15 Hoffmann La Roche Verfahren zur synthese von aryloxydiaminopyrimidinen
SI1924264T1 (sl) * 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
DK2343281T3 (en) * 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
WO2008104474A1 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Diaminopyrimidines

Also Published As

Publication number Publication date
SI2343281T1 (sl) 2014-06-30
KR101176701B1 (ko) 2012-08-23
IL254426A0 (en) 2017-11-30
IL197639A0 (en) 2009-12-24
ES2461595T3 (es) 2014-05-20
MX2009003257A (es) 2009-04-07
BRPI0719955B1 (pt) 2024-01-09
PL2343281T3 (pl) 2014-08-29
CA2664305A1 (en) 2008-04-10
IL234545A (en) 2017-10-31
US20080086004A1 (en) 2008-04-10
CN102432548A (zh) 2012-05-02
US8003788B2 (en) 2011-08-23
JP5128603B2 (ja) 2013-01-23
AU2007304280B2 (en) 2013-01-31
EP2343281A1 (en) 2011-07-13
DK2343281T3 (en) 2014-03-24
US20140045871A1 (en) 2014-02-13
KR20090055043A (ko) 2009-06-01
JP2010505790A (ja) 2010-02-25
US8580960B2 (en) 2013-11-12
EP2343281B1 (en) 2014-03-05
AU2007304280A1 (en) 2008-04-10
CN101522641A (zh) 2009-09-02
ES2466667T3 (es) 2014-06-10
IL197639A (en) 2015-02-26
JP5669793B2 (ja) 2015-02-18
EP2079713A1 (en) 2009-07-22
CN101522641B (zh) 2012-07-04
US20110269961A1 (en) 2011-11-03
CA2664305C (en) 2016-06-07
EP2079713B1 (en) 2014-04-16
US9643934B2 (en) 2017-05-09
WO2008040652A1 (en) 2008-04-10
JP2013010780A (ja) 2013-01-17

Similar Documents

Publication Publication Date Title
BRPI0819602A2 (pt) Processo para produzir gás de síntese de amônia
BRPI0814327A2 (pt) Processo para produzir gás de síntese de amônia
BRPI0910689A2 (pt) processo de síntese de rna por via química
BRPI0819659A2 (pt) Processo para produção de álcool
BRPI0816258A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt
PT2155838E (pt) Processo de produção de hidrocarbonetos ramificados
BRPI0820689A2 (pt) processo de produção de um derivado de indolinona
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
BRPI0807626A2 (pt) Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase
CR10562A (es) Nuevos derivados de piridazina
BRPI0718440A2 (pt) Processo de preparo de halogenetos de n-alquinaltrexona
ES2380489T8 (es) Proceso para la síntesis de compuestos orgánicos
PT2155839E (pt) Processo de produção de hidrocarbonetos ramificados
BRPI0814457A2 (pt) Derivados de imidazolona, composições farmacêuticas, utilização de derivados de imidazolona, e, processo de síntese de derivados de imidazolona
BRPI0612898A2 (pt) processo para produzir gás de síntese
IL254426A0 (en) A process for the preparation of phenoxy diaminopyrimidine derivatives
EP2019118A4 (en) METHOD FOR SYNTHETIZING THYMOSINS
BRPI0816911A2 (pt) Processo para preparação de 4-aminobut-2-enolidas
DK2029567T3 (da) Fremgangsmåde til frembringelse af benzopyran-2-ol-derivater
BRPI0910545A2 (pt) processo contínuo para fazer composições farmacêuticas
BRPI0814012A2 (pt) Processo para produção de (met)acrilatos
BRPI0813960A2 (pt) Processo para produção de biarilas
BRPI0813788A2 (pt) Processo para preparação de metacrilato de alila
BRPI0910675A2 (pt) Processo para preparação de intermediários de naftalen-2-ilpirazol-3-ona úteis na síntese dos inibidores de receptores sigma
BRPI0915177A2 (pt) processo para fazer 2-amino-tiazolonas substituídas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/09/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.